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18F-FDG PET is a useful and sensitive imaging method for a variety of malignancies, however, the speciﬁcity is low in active
infections and inﬂammatory diseases. We describe a female patient with stage IIIA breast cancer in ﬁrst complete remission with
combinationchemotherapywhodevelopednodularformationsinthelungandaxilla12yearslater.ImagingstudiesaswellasFDG
PET showed nodular lesions and increased metabolic activity which was interpreted as the progression of the primary disease. She
was ﬁrst given combination chemotherapy and hormonal therapy but was proven thereafter to have sarcoidosis by pathologic
examination and was successfully treated with corticosteroid treatment.
Copyright © 2009 Selmin Ataergin et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Sarcoidosis is a chronic multisystem disorder which is
characterized by the accumulation of T lymphocytes and
mononuclear phagocytes, noncaseating epitheloid granulo-
mas in aﬀected organs, and derangements of the normal
tissue architecture. Although the etiology is unknown, it
is thought to be caused by exaggerated cellular immune
responses. The ﬁrst pathologic manifestation of the disease
is the accumulation of mononuclear inﬂammatory cells,
mainly CD4+ T helper 1 lymphocytes and mononuclear
phagocytesintheaﬀectedorgans.Thisinﬂammatoryprocess
is followed by the formation of granulomas, aggregates of
macrophages, and epitheloid cells, as well as multinucleated
giant cells [1]. There is no established relation between
sarcoidosis and cancer, however, they can coexist. Battesti
described seven cases of cancer in 580 patients with sar-
coidosis [2]. Several types of tumors have been reported to
be involved [3]. The observation of sarcoidosis after cancer
would suggest a relation between both conditions.
Diﬀerentiation of malignant from benign nodules is a
common dilemma in diagnostic imaging. Metabolic imag-
ing with 2-(18F)-ﬂuoro-2-deoxy-D-glucose (FGD) positron
emission tomography (PET) is being used more and more to
diﬀerentiate benign from malignant focal lesions [2, 3]a n d
it has been shown to be more eﬃcacious than conventional
computed tomography (CT) [4]. However, FDG is not a
cancer-speciﬁc agent, and benign diseases related mainly
to infection or inﬂammation also can show false-positive
intense FDG uptake which causes diﬃculty in diﬀerentiating
benign disorders from malignant diseases [3–7].
2.CaseReport
A 63-year-old woman was diagnosed T3N1M0 right-sided
breastcancer12yearsagoandachievedacompleteremission
after the administration of 6 courses of CAF (cyclophos-
phamide, doxorubicin, 5-FU) chemotherapy and radiother-
apy. On her admittance to another institution twelve years
later, right-sided minimal pleural eﬀusion was detected on
CT. Although cytologic examination of the pleural ﬂuid was
negative for malignancy, CA-15-3 level was slightly elevated
and CEA level was within the normal ranges. Any pathogen
could not be detected by microbiological examinations. Due
to a previous history of breast cancer, a chemotherapy2 Case Reports in Medicine
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Figure 1: Coronal FDG-PET images showed a focus of mildly increased FDG activity (SUV max = 2,1) in the medial segment of the upper
lobe in the left lung (dotted arrows) and multiple moderate to markedly increased FDG foci (SUV max = 3,4) in the right-sided axillary
lymphnodes(arrows)ina63-year-oldwoman, whounderwentFDG-PETscanfortheevaluation ofenlarged rightaxillarylymphnodesand
lung nodules, for the detection of recurrent metastatic breast cancer disease. Histopathologic examination of the axillary and endobronchial
lesions revealed sarcoidosis.
regimen consisting of paclitaxel and farmarubicin was ini-
tiated. Pulmonary nodular lesions measuring 1cm in the left
lung, and axillary lymph nodes of 0.8cm were detected on
control CT after 4 months, but the patient refused a biopsy.
Letrozole was initiated during the persuation period of the
patient for biopsy. F-18 FDG PET revealed abnormal FDG
accumulation in the left lung with mild metabolic activity
(SUV max: 2.1), and also moderately high metabolic activity
(SUV max: 3.4) related to multiple lymph nodes in the
right axilla (Figure 1). Finally, the patient was convinced
for an excisional biopsy from axillary lymph node as well
as endobronchial lymph node biopsy, which were revealed
sarcoidosis. All pathologic imaging ﬁndings regressed after
corticosteroid treatment.
3. Discussion
We described a female patient with stage IIIA breast cancer
who developed nodular formations in the left lung and
in the right-sided axillary lymph nodes 12 years after the
achievement of a complete response. FDG PET showed low
to moderately increased metabolic activity which was ﬁrst
interpreted as the progression of the primary disease, but
conﬁrmed thereafter pathologically to be sarcoidosis.
Metabolic imaging with FDG-PET has gained an impor-
tant role in the management of oncologic diseases. However,
false positive FDG uptake or false-negative PET scans are
frequently encountered. Proper interpretation and accurate
characterization of an abnormality can be accomplished
only if one is aware of possible false-positive or negative
conditions. FDG PET is able to image the metabolic
diﬀerences between normal and malignant cells according
to glucose metabolism of a lesion, which can be helpful in
diﬀerentiating benign and malignant lesions [14]. Malignant
cells demonstrate higher glucose metabolic activity than
benign lesions do. Moreover, the total of FDG uptake is
not completely within the tumor cells themselves. The
newly formed granulation tissue around the tumor and
the macrophages inﬁltrating heavily at the marginal areasCase Reports in Medicine 3
Table 1: Published sarcoidosis cases detected by 18 F FDG-PET∗ study in cancer patients.
Reference Author Publication year Primary cancer Number of cases Age Sex
[8] Takanami et al. 2008 Esophagus cancer 2 48 and 50 M
[9] Li et al. 2007 Lymphoma 1 45 F
[10] Kunstman et al. 2007 Ovarian cancer 1 55 F
[11] Maeda et al. 2005 Lung cancer 1 66 M
[12] de Hemricourt et al. 2003 Hodgkin’s disease 2 38 M
[13] Muggia et al. 1998 Seminoma 1 41 M
∗2-(18F)-ﬂuoro-2-deoxy-D-glucose positron emission tomography.
surrounding the necrotic area of the tumor may show high
FDG uptake. On the other hand, active granulomatous
processes such as tuberculosis [3, 5, 6], fungal infections [7],
and sarcoidosis [8–13] have been reported to accumulate
FDG and cause false-positive PET scans for malignancy
(Table 1). High FDG uptake in activated inﬂammatory cells
is due to markedly increased glycolysis and the hexose
monophosphate shunt which is stimulated by phagocytosis,
with increases of 20–30 times of baseline values [15]. As a
result, approximately 24% of the FDG concentration in a
tumormassisderivedfromnontumortissue[16].Therefore,
acute or chronic infection or inﬂammation must always be
considered as a potential false-positive ﬁnding when whole-
body F-18 FDG PET scans are interpreted, especially in
patients with previous history of cancer.
In sarcoidosis, the cellular inﬁltrate is composed of
lymphocytes, macrophages, and epitheliod cells, and can
involve almost any organ. The disease process is believed
to initially involve pulmonary interstitial tissue with the
formation of noncaseating granulomas, which are character-
istic of the disease. In sites of active inﬂammatory disease,
rapidly dividing cells, such as inﬂammatory cells, have a
high glycolytic activity. Besides, macrophages are known to
havehighratesofproteinsecretionandmembranerecycling,
resulting in increased FDG uptake. As expected, the role
of FDG PET imaging in the diagnosis of sarcoidosis is
limited. However, in a patient with proven sarcoidosis, both
the extent of involvement and disease activity can be more
accurately assessed by FDG PET than other methods such as
Ga-67 Sitrate scintigraphy [17].
As discussed earlier, pulmonary granulomatous diseases,
such as tuberculosis, sarcoidosis, fungal infections, and also
any kind of infection, may predispose to localized FDG
thoracic uptake, and limit the speciﬁcity of FDG PET scan
by mimicking metastases. Although being nonspeciﬁc, given
the patients young age, and lack of history of primary
malignancy, the ﬁndings of multiple bilateral pulmonary
nodules with associated mediastinal and symmetrical hilar
lymphadenopathyonFDG PETscanaremoresuggestiveofa
granulomatous disorder, or an infectious process rather than
pulmonary metastases. In a patient on a complete remission
after treatment for low-grade tumor pathology, similar FDG
PET ﬁndings are more suggestive for benign conditions,
especially if the patient has normal clinical examination with
no other radiologic or laboratory abnormality indicating
recurrence. However, as in this particular case, since both
sarcoidosis and breast cancer may have the potential to
invade the lymphoid systems throughout the body, the
uptake pattern on FDG PET images may be nonspeciﬁc, and
cannot diﬀerentiate granulomatous disease from malignant
conditions.
Many benign conditions that can cause high uptake of
18-FDG and have the potential for false-positive interpre-
tation in oncologic studies have previously been described
[18]. These false-positive FDG uptakes may mimic speciﬁc
cancer types according to its localization. For example, focal
asymmetric neck muscle uptake, focal bowel uptake, or focal
ureter uptake may mimic cervical, mesenteric, or peritoneal
and paraaortic or iliac lymph node metastases, respectively.
Moreover, lymphatic drainage of the extravasated tracer
from the injection site to the axillary lymph nodes may
cause misinterpretation of the FDG PET scans as axillary
lymph node metastasis. In the skeleton, diﬀuse increase in
bone marrow activity seen as a result of chemotherapy or
colony stimulating factors is now well recognized. Thymus
hyperplasia may also mimic thymic disease and anterior
mediastinal involvement. On the other hand, diﬀerential
diagnosis of normal ovarian and endometrial uptake from
gynecological benign or malignant disease is a well-known
problem. In many instances, these physiologic variants and
benign pathological causes of FDG uptake can be speciﬁcally
recognized and properly categorized; in other instances
FDG uptake may reﬂect nonspeciﬁc clinical importance [18,
19].
Conversely, there are a number of malignant tumors
that show little or no FDG uptake decreasing the negative
predictive value of FDG PET scan. For example, very small
lungmetastasesmaybebeyondtheresolutionofcurrentPET
scanners. Mucosa-associated lymphoid tissue lymphomas,
small lymphocytic cell lymphoma, and well-diﬀerentiated
neuroendocrine tumors may show only low-grade activity
that may be inconspicuous. On the other hand, sclerotic
bone metastases, renal cell carcinoma, and brain metastases
also can be inconspicuous on occasion, either because of low
uptake or high surrounding background activity [19].
The most widely applied PET radiopharmaceutical in
oncology is 18F-FDG. However, 18F-FDG PET is not 100%
accurate in the detection of primary tumors and their metas-
tases. Therefore, more speciﬁc PET radiopharmaceuticals
are needed. To increase the accuracy of FDG PET imaging,
several PET tracers other than 18F-FDG have been studied.
The fact that amino acid imaging is less inﬂuenced by4 Case Reports in Medicine
inﬂammation may be advantageous in comparison with 18F-
FDGPETimaging,althoughtumorspeciﬁcityisnotabsolute
[20]. Among the tracers other than 18F-FDG, C-11-labelled
amino acid agents are very promising. Amino acid transport
is generally increased in malignant cells and amino acid
imaging is less inﬂuenced by inﬂammation. For example,
C-11 thymidine is used in the evaluation of tumor DNA
replication and cell division rates, and C-11 choline (11C-
CHOL) is an agent which reﬂects cell membrane synthesis.
These agents may contribute for the diﬀerential diagnosis
of FDG uptake in patients suspicious for malignancy [20,
21].
The presented case should be an educational case in
terms of demonstrating the importance of patient-doctor
collaboration, and all patients should be convinced for
a biopsy in suspected situations before the initiation of
a deﬁnitive anticancer treatment. In conclusion, if any
abnormal FDG accumulation is detected on FDG PET study
in lymph nodes or parenchyma of a patient with a previous
history of cancer, the diagnosis of cancer should always be
conﬁrmed pathologically to exclude false-positive FDG PET
ﬁndings.
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